Atrial FibrillationNCT02309398
CCC Project - Atrial Fibrillation
An observational study of Atrial Fibrillation, run by Beijing Institute of Heart, Lung and Blood Vessel Diseases at 1 site in China.
Trial summary
The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Atrial Fibrillation
- How many people
- 67,028 participants
- Where
- 1 siteChina
- Study dates
- Jan 2015to Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Hospitalized patients of atrial fibrillation
Who may be able to join
- Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation
The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.
- Conditions
- Atrial Fibrillation
- Medical subject headings
- Atrial Fibrillation
What is being measured
The primary outcome is the main question the study is designed to answer.
The overall composite of six performance measures for AF care
Performance measures for AF care including:
- Proportion of patients received assessment of thromboembolic risk factors
- Proportion of patients discharged on warfarin or other anticoagulant drug
- Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge
- Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge
- Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge
- Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge
Measured: Duration of hospital stay, an expected average of 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2014 (estimated)
- Study startJan 2015
- Primary completionDec 2020
- Study completionDec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 67,028 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Sponsor type
- University, hospital or other
- Collaborators
- American Heart Association, Chinese Society of Cardiology
- Responsible party
- Principal investigator, Dong ZHAO, Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Investigators
- Dong Zhao, Ph. D, Principal investigator, Beijing Institute of Heart, Lung and Blood Vessel Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02309398
- Sponsor's protocol ID
- CCC-AF-2014
- Status last verified
- Jan 2021
- First submitted
- 30 Nov 2014
- Last updated
- 27 Jan 2021
- Results posted
- No
Publications
Hao Y, Liu J, Smith SC, Huo Y, Fonarow GC, Ge J, Liu J, Taubert KA, Morgan L, Guo Y, Zhou M, Zhao D, Ma C; CCC-AF Investigators. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018 Jul 5;8(7):e020968. doi: 10.1136/bmjopen-2017-020968.
PubMed 29980544Han K, Li X, Fu B, Li M, Liu T, Peng Y, Liu J, Yang N, Hao Y, Jiang C, Tang R, Dong J, Zhao D, Long D, Ma C. Elevated Resting Heart Rate in Hospitalized Patients With Atrial Fibrillation Is Associated With Increased Cardiovascular Risk. Cardiovasc Ther. 2026 Jan 26;2026:2106637. doi: 10.1155/cdr/2106637. eCollection 2026.
PubMed 41608332Tong XY, Lin J, Sun ZQ, He Q, Zhan Y, Jiang CX, Tang RB, Sang CH, Ning M, Jia CQ, Feng L, Wang W, Zhao X, Li CY, Li SN, Guo XY, Liu T, Li MM, Yang N, Hao YC, Liu J, Liu J, Xie J, Long DY, Dong JZ, Zhao D, Ma CS. Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients with atrial fibrillation: findings from CCC-AF project. Front Cardiovasc Med. 2025 Jun 12;12:1574796. doi: 10.3389/fcvm.2025.1574796. eCollection 2025.
PubMed 40574812Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J; CCC-AF Investigators. Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. BMJ Open. 2025 Feb 22;15(2):e088539. doi: 10.1136/bmjopen-2024-088539.
PubMed 39986999Xia Y, Jiang J, Fan F, Pan Y, Zhou J, Zhang Y, Li J, Liu J, Yang N, Hao Y, Zhao D, Liu J, Ma C, Huo Y; CCC-AF investigators. Prevalence, Characteristics, and Treatment Strategy of Different Types of Heart Failure in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2024 Oct;13(19):e033941. doi: 10.1161/JAHA.123.033941. Epub 2024 Sep 30.
PubMed 39344652Lin J, Long D, Jiang C, Sang C, Tang R, Li S, Wang W, Guo X, Ning M, Sun Z, Yang N, Hao Y, Liu J, Liu J, Du X, Morgan L, Fonarow GC, Smith SC Jr, Lip GYH, Zhao D, Dong J, Ma C; CCC-AF investigators. Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation. Chin Med J (Engl). 2024 Jan 20;137(2):172-180. doi: 10.1097/CM9.0000000000002915. Epub 2023 Dec 22.
PubMed 38146256He P, Pan Y, Jiang J, Fan F, Zhou J, Xia Y, Liu J, Yang N, Hao Y, Li J, Liu J, Zhao D, Huo Y; CCC-AF investigators. In-hospital therapies and determinants of treatment strategy selection in patients with atrial fibrillation and left ventricular systolic dysfunction in China: a retrospective study based on the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation (CCC-AF) project, 2015-2019. BMJ Open. 2023 Jun 5;13(6):e070070. doi: 10.1136/bmjopen-2022-070070.
PubMed 37277219
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT02309398
- Acronym / sponsor ID
- CCC-AF-2014
- Conditions
- Atrial Fibrillation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 67,028 participants (actual)
- Lead sponsor
- Beijing Institute of Heart, Lung and Blood Vessel DiseasesUniversity, hospital or other
- Collaborators
- American Heart Association, Chinese Society of Cardiology
- Study start
- Jan 2015
- Primary completion
- Dec 2020 (actual)
- Study completion
- Dec 2020 (actual)
- First posted
- 5 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Hospitalized patients of atrial fibrillation
Key inclusion criteria (1 listed)
- Hospitalized patients with discharge diagnosis as atrial fibrillation in 150 tertiary and 100 secondary hospitals.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The overall composite of six performance measures for AF care
Time frame: Duration of hospital stay, an expected average of 1 week
Performance measures for AF care including: 1. Proportion of patients received assessment of thromboembolic risk factors 2. Proportion of patients discharged on warfarin or other anticoagulant drug 3. Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge 4. Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge 5. Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge 6. Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2021.
- Results publication: PubMed 29980544Hao Y, Liu J, Smith SC, Huo Y, Fonarow GC, Ge J, Liu J, Taubert KA, Morgan L, Guo Y, Zhou M, Zhao D, Ma C; CCC-AF Investigators. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018 Jul 5;8(7):e020968. doi: 10.1136/bmjopen-2017-020968.
- Derived from this study: PubMed 41608332Han K, Li X, Fu B, Li M, Liu T, Peng Y, Liu J, Yang N, Hao Y, Jiang C, Tang R, Dong J, Zhao D, Long D, Ma C. Elevated Resting Heart Rate in Hospitalized Patients With Atrial Fibrillation Is Associated With Increased Cardiovascular Risk. Cardiovasc Ther. 2026 Jan 26;2026:2106637. doi: 10.1155/cdr/2106637. eCollection 2026.
- Derived from this study: PubMed 40574812Tong XY, Lin J, Sun ZQ, He Q, Zhan Y, Jiang CX, Tang RB, Sang CH, Ning M, Jia CQ, Feng L, Wang W, Zhao X, Li CY, Li SN, Guo XY, Liu T, Li MM, Yang N, Hao YC, Liu J, Liu J, Xie J, Long DY, Dong JZ, Zhao D, Ma CS. Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients with atrial fibrillation: findings from CCC-AF project. Front Cardiovasc Med. 2025 Jun 12;12:1574796. doi: 10.3389/fcvm.2025.1574796. eCollection 2025.
- Derived from this study: PubMed 39986999Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J; CCC-AF Investigators. Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. BMJ Open. 2025 Feb 22;15(2):e088539. doi: 10.1136/bmjopen-2024-088539.
- Derived from this study: PubMed 39344652Xia Y, Jiang J, Fan F, Pan Y, Zhou J, Zhang Y, Li J, Liu J, Yang N, Hao Y, Zhao D, Liu J, Ma C, Huo Y; CCC-AF investigators. Prevalence, Characteristics, and Treatment Strategy of Different Types of Heart Failure in Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2024 Oct;13(19):e033941. doi: 10.1161/JAHA.123.033941. Epub 2024 Sep 30.
- Derived from this study: PubMed 38146256Lin J, Long D, Jiang C, Sang C, Tang R, Li S, Wang W, Guo X, Ning M, Sun Z, Yang N, Hao Y, Liu J, Liu J, Du X, Morgan L, Fonarow GC, Smith SC Jr, Lip GYH, Zhao D, Dong J, Ma C; CCC-AF investigators. Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation. Chin Med J (Engl). 2024 Jan 20;137(2):172-180. doi: 10.1097/CM9.0000000000002915. Epub 2023 Dec 22.
- Derived from this study: PubMed 37277219He P, Pan Y, Jiang J, Fan F, Zhou J, Xia Y, Liu J, Yang N, Hao Y, Li J, Liu J, Zhao D, Huo Y; CCC-AF investigators. In-hospital therapies and determinants of treatment strategy selection in patients with atrial fibrillation and left ventricular systolic dysfunction in China: a retrospective study based on the Improving Care for Cardiovascular Disease in China-Atrial Fibrillation (CCC-AF) project, 2015-2019. BMJ Open. 2023 Jun 5;13(6):e070070. doi: 10.1136/bmjopen-2022-070070.
Related trials for Atrial Fibrillation
Active, not recruitingObservational study
FARAPULSE™ Pulsed Field Ablation System
Paroxysmal AF
Not yet recruiting
Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Atrial Fibrillation (AF), Ablation Treatment
Recruiting
OPTION-EMEA Clinical Trial
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
Active, not recruiting
A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF
Atrial Fibrillation
Not yet recruiting
Mobile Clinic-Supported, Village Doctor-Led Screening and Integrated Care for Atrial Fibrillation and Heart Failure Comorbidity in Rural China (MOVE-AF HF)
Atrial Fibrillation (AF), Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dong Zhao, Ph. D principal investigator
Beijing Institute of Heart, Lung and Blood Vessel Diseases
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by Beijing Institute of Heart, Lung and Blood Vessel Diseases at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The overall composite of six performance measures for AF care (time frame: Duration of hospital stay, an expected average of 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02309398, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2021.